The DMD BMD Mutation Screening 26 Exons Test is a specialized genetic test conducted at DNA Labs UAE, designed to identify mutations in 26 specific exons of the DMD gene, which is responsible for Duchenne and Becker muscular dystrophies (DMD and BMD). These conditions are among the most common forms of muscular dystrophy, characterized by progressive muscle weakness and degeneration. Early and accurate detection of mutations in these exons can help in the diagnosis, management, and treatment planning for individuals affected by these disorders. The test is priced at 1500 AED, making it accessible for individuals seeking comprehensive genetic analysis in the UAE. DNA Labs UAE is equipped with advanced genetic testing facilities to ensure accurate and reliable results for patients and their families.
The EWSR1 Gene Ewing's Sarcoma Test is a sophisticated diagnostic procedure aimed at identifying the presence of specific genetic rearrangements associated with Ewing's sarcoma, a rare type of cancer that typically affects bones or the soft tissue around bones. This test focuses on detecting abnormalities in the EWSR1 gene, which are crucial for diagnosing the condition, determining prognosis, and guiding treatment decisions.
Performed at DNA Labs UAE, a state-of-the-art facility known for its advanced genetic testing services, this test offers a reliable solution for patients and healthcare providers dealing with Ewing's sarcoma. The test cost is set at 1500 AED, reflecting the comprehensive analysis and expert interpretation involved in identifying the genetic markers associated with this aggressive cancer. By opting for this test, patients can gain valuable insights into their condition, enabling timely and targeted treatment interventions.
The FLT3ITD Allelic Ratio Test is a specialized genetic test designed to identify mutations in the FLT3 gene, specifically the internal tandem duplication (ITD) mutations, which are common in acute myeloid leukemia (AML) patients. This test plays a crucial role in the diagnosis, prognosis, and management of AML by determining the allelic ratio of the FLT3ITD mutation. The allelic ratio, which is the proportion of mutant FLT3 to wild-type FLT3, can influence treatment decisions and predict patient outcomes. A higher allelic ratio is often associated with a worse prognosis.
Conducted by DNA Labs UAE, a reputable laboratory known for its advanced genetic testing services, the FLT3ITD Allelic Ratio Test is priced at 1520 AED. The test is performed using sophisticated molecular techniques to ensure accurate and reliable results, which are essential for guiding the therapeutic approach and monitoring disease progression in AML patients. With its state-of-the-art facilities and expert staff, DNA Labs UAE provides a vital service to patients and healthcare providers, contributing to the personalized treatment of acute myeloid leukemia.
Fragile X Syndrome (FXS) is a genetic disorder that causes intellectual disability, behavioral challenges, and various physical characteristics. It is the most common form of inherited intellectual disability in males and a significant cause of intellectual disability in females. The disorder is linked to mutations in the FMR1 gene located on the X chromosome. These mutations lead to the production of an abnormal form of the protein needed for brain development.
The Polymerase Chain Reaction (PCR) test for Fragile X Syndrome is a specialized diagnostic tool used to detect the presence of mutations in the FMR1 gene. This test amplifies a small segment of the FMR1 gene's DNA, allowing for the examination of its structure and the identification of any abnormalities that indicate Fragile X Syndrome. The PCR test is known for its high sensitivity and specificity in detecting various types of mutations, including the number of CGG repeats in the FMR1 gene, which is crucial for diagnosing Fragile X Syndrome.
In the United Arab Emirates, DNA Labs UAE offers this sophisticated testing service. The cost of the Fragile X Syndrome FMR1 detection by PCR test at DNA Labs UAE is 1500 AED. This facility is equipped with state-of-the-art technology and staffed by experienced professionals who ensure accurate and reliable test results. Opting for this test at DNA Labs UAE can provide families with crucial information regarding Fragile X Syndrome, facilitating early diagnosis and the opportunity for timely intervention and support.
The Huntington Disease (HD) Mutation Screening Test is a crucial diagnostic tool available at DNA Labs UAE, designed to identify the presence of genetic mutations associated with Huntington's disease. Priced at 1600 AED, this test specifically looks for the expanded CAG repeats in the HTT gene, which are indicative of the disease. Huntington's disease is an inherited condition characterized by the progressive degeneration of nerve cells in the brain, leading to physical, cognitive, and emotional symptoms. Early detection through the HD Mutation Screening Test can be vital for individuals with a family history of the condition, enabling them to make informed decisions about their future health and lifestyle. DNA Labs UAE utilizes advanced genetic testing techniques to ensure accurate and reliable results, providing crucial information for the management and understanding of this challenging condition.
The IGVH Mutation Load Test is a sophisticated diagnostic procedure offered by DNA Labs UAE, aimed at patients with chronic lymphocytic leukemia (CLL). This test evaluates the mutational status of the immunoglobulin heavy chain variable region (IGHV) gene, which is crucial for predicting the disease's progression and guiding treatment strategies. A high mutation load in the IGVH gene is generally associated with a more favorable prognosis and may influence the choice of therapeutic approaches. Priced at 1600 AED, this test provides vital information for clinicians to tailor treatment plans more effectively, enhancing the potential for positive outcomes in CLL patients.
The "Irinotecan Toxicity Assessment UGT1A1 Genotyping Gilbert Syndrome Test" is a specialized diagnostic examination offered by DNA Labs UAE, designed to evaluate an individual's risk of experiencing toxicity from the chemotherapy drug irinotecan. Priced at 1500 AED, this test is particularly significant for patients undergoing or considering treatment for cancers such as colorectal cancer, where irinotecan is commonly prescribed.
Irinotecan toxicity is largely influenced by the activity of the UGT1A1 enzyme, which is responsible for metabolizing the drug in the body. Variations in the UGT1A1 gene can lead to reduced enzyme activity, resulting in increased drug toxicity and adverse side effects. The test focuses on genotyping the UGT1A1 gene to identify any mutations associated with Gilbert Syndrome, a common genetic condition that reduces UGT1A1 enzyme activity. Individuals with Gilbert Syndrome are at a higher risk of experiencing severe toxicity from irinotecan treatment.
By assessing the UGT1A1 gene status, the test helps oncologists personalize cancer treatment plans, potentially avoiding irinotecan for patients with a high risk of toxicity and exploring alternative therapies. This tailored approach not only enhances the efficacy of the treatment but also significantly reduces the likelihood of adverse effects, improving the overall quality of life for cancer patients.
Conducted at DNA Labs UAE, a leading facility known for its advanced genetic testing services, this assessment is a crucial step for patients and healthcare providers in optimizing cancer treatment strategies, ensuring both safety and effectiveness in the battle against cancer.
Karyotyping for the detection of Fragile X Syndrome is a specialized genetic test aimed at identifying abnormalities in the X chromosome that are indicative of this condition. Fragile X Syndrome is a genetic disorder that causes a range of developmental problems, including learning disabilities and cognitive impairment. It is caused by a defect in the FMR1 gene on the X chromosome, where the DNA makes too many copies of itself and does not function properly.
The test involves collecting a sample of the patient's blood and analyzing the chromosomes present in the sample's cells. Specifically, technicians look for the presence of an abnormal number of CGG repeats in the FMR1 gene, which is characteristic of Fragile X Syndrome. The process requires sophisticated laboratory equipment and expertise in genetic analysis to accurately diagnose the condition.
At DNA Labs UAE, the test for detecting Fragile X Syndrome through karyotyping is available for a cost of 1500 AED. DNA Labs UAE is equipped with state-of-the-art technology and staffed by professionals skilled in genetic testing and analysis, ensuring accurate and reliable results. The test provides crucial information for families and individuals at risk of Fragile X Syndrome, facilitating early diagnosis and intervention strategies that can significantly improve quality of life.
**Large Biopsy 5 Post Chemotherapy Bone Test at DNA Labs UAE**
The "Large Biopsy 5 Post Chemotherapy Bone Test" is a specialized diagnostic procedure offered by DNA Labs UAE, designed for patients who have undergone chemotherapy. This test plays a crucial role in evaluating the effects of chemotherapy on bone health and detecting any potential changes or damage to bone tissue that may have occurred as a result of the treatment. By examining a large biopsy sample, the test provides comprehensive insights into the bone's structural integrity, the presence of any residual cancer cells, and the overall impact of chemotherapy on the bone marrow.
Performed by a team of experienced professionals at DNA Labs UAE, this test ensures accuracy and reliability in results. The procedure involves the collection of a sizable biopsy from the bone, which is then subjected to detailed analysis using advanced laboratory techniques. This thorough examination helps in guiding further treatment decisions, monitoring recovery, and implementing preventive measures to safeguard bone health.
The cost of the "Large Biopsy 5 Post Chemotherapy Bone Test" is set at 1500 AED. Given the complexity of the test and the invaluable information it provides, it represents a critical investment in the post-chemotherapy care and management of patients. DNA Labs UAE is committed to delivering exceptional care and precise diagnostic services, making it a trusted choice for patients and healthcare providers alike.
The H7N7 and Influenza A RNA Detection Qualitative Test is a specialized diagnostic procedure aimed at identifying the presence of RNA from the H7N7 strain, as well as other Influenza A viruses, in a patient's sample. This test is crucial for the early detection and management of infections caused by these viruses, which are known for their potential to cause severe respiratory illnesses in humans. Utilizing advanced molecular techniques, this test can qualitatively determine whether the RNA of these viruses is present, aiding in the swift diagnosis and treatment of affected individuals.
Performed at DNA Labs UAE, a leading facility in the field of molecular diagnostics, the test ensures high accuracy and reliability. The cost of the test is set at 1770 AED, reflecting the sophisticated technology and expertise involved in conducting the analysis. By offering this test, DNA Labs UAE plays a vital role in the public health response to influenza outbreaks, contributing to the containment and management of potential epidemics caused by the H7N7 and other Influenza A viruses.
